De verlaging van de concentraties aan co-enzym Q10 (ubiquinol) in het verouderende hart én de vaststelling dat deze bij diverse hartziekten nog lager liggen, bv. bij hartfalen, heeft ertoe geleid dat dit het eerste gebied was waar de werking van Q10 bestudeerd werd. Dit is ook zeer logisch: het hart is allicht het orgaan dat de hoogste energiebehoefte heeft én bovendien zeer gevoelig is voor oxidatieve stress. Daling van de mitochondriale capaciteit en Q10-voorraad en verlaging van de antioxidatieve capaciteit zal zich dus vaak het snelst daar manifesteren.
Beste bezoeker, u heeft geen toegang.
Enkel (web)abonnees hebben toegang tot tijdschriftartikelen. Het webabonnement is nog in de maak.
U kunt zich wel alvast (gratis) registreren en tal van andere webartikelen raadplegen!
Auteur
Trefwoorden:
Verschenen in
Referenties
(extra referenties)
1. Faché WA. Co-enzym Q10, klinische relevantie in de cardiologie.
2. Langsjoen PH, et al. Overview of the use of CoQ10 in cardiovascular disease. Biofactors. 1999;9(2-4):273-84.
3. Crane FL. The evolution of coenzyme Q. Biofactors. 2008;32(1-4):5-11.
4. Pepe S et al. Coenzyme Q10 in cardiovascular disease. Mitochondrion 2007; 7S:154-67.
5. Singh U et al. Coenzyme Q10 supplementation and heart failure. Nutr Rev 2007; 65(6):286-93
6. Vormann J. Coenzyme Q10. AgroFOOD mei/juni 2004
7. Molyneux SL et al. Coenzyme Q10, An Independent Predictor of Mortality in Chronic Heart Failure. J Am Coll Cardiol 2008; 52(18).
8. Sanders S, et al. The impact of coenzym Q10 on systolic function in patients with chronic heart failure: meta-analysis. J Card Fail. 2006.
9. Tiano L, Littaru GP. Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study. Eur Soc Cardiol 2007; 28(18): 2249-2255.
10. Schmelzer C et al. Effects of the Reduced Form of CoQ10 on Secretion Levels of TNF-α and Chemokines in Response to LPS in the Human Monocytic Cell Line THP-1. J Clin Biochem Nutr:2009; 444:1-5.
11. Schmelzer C, Okun JG, Haas D, Higuchi K, Sawashita J, Mori M, Döring F. The reduced form of coenzyme Q(10) mediates distinct effects on cholesterol metabolism at the transcriptional and metabolite level in SAMP1 mice. IUBMB Life. 2010 Nov;62(11):812-8.
12. Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control in a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr. 2002 Nov;56(11):1137-42.
13. Rosenfeldt FL, Watts GF et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials.
14. Langsjoen PH, Langsjoen AM. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors 2008; 32:119-28.
15. Makhija N et al. The Role of Oral Coenzyme Q10 in Patients Undergoing Coronary Artery Bypass Graft Surgery. J Cardiothorac Vasc Anesth. 2008 Jun 5. [Epub ahead of print]
16. Belardinelli R, Littaru GP et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J online 2006, Aug 1.
17. Caso G et al. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007; 15;99(10):1409-12
18. Langsjoen P, et al. Effect of atorvastin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol. 2004:
19. Chu CS, et al; Biofactors 2006 en Lamperti C, et al; Arch Neurol. 2005: Depletie van coënzym Q10 in spierweefsel
20. Joy TR and Hegele RA. Narrative Review: Statin-Related Myopathy. Ann Intern Med. 2009;150:858-868.
21. Cleland JGF, Clarck AL et al. Threats, opportunities, and statins in the modern management of heart failure. European Heart Journal (2006) 27, 641-643
